PMID- 20679904
OWN - NLM
STAT- MEDLINE
DCOM- 20110713
LR  - 20131121
IS  - 1539-2031 (Electronic)
IS  - 0192-0790 (Linking)
VI  - 45
IP  - 4
DP  - 2011 Apr
TI  - A new PPI, ilaprazole compared with omeprazole in the treatment of duodenal 
      ulcer: a randomized double-blind multicenter trial.
PG  - 322-9
LID - 10.1097/MCG.0b013e3181e88515 [doi]
AB  - GOALS: To investigate the efficacy and safety of a new proton pump inhibitor 
      (PPI), ilaprazole (IY-81149) in the treatment of duodenal ulcers and provide some 
      characteristics of the dose-response relationship for later studies. BACKGROUND: 
      PPIs have been used therapeutically for many years, and shown great efficacy in 
      accelerating ulcer healing. Currently researches are focused on more potent PPIs. 
      Some preclinical studies have shown that ilaprazole might be such a new 
      substitute. STUDY: 235 patients with at least 1 endoscopically diagnosed active 
      duodenal ulcer were enrolled in a randomized trial. Patients were randomized into 
      4 groups (5, 10, and 20 mg/d ilaprazole, with 20 mg/d omeprazole as positive 
      control) and treated for up to 4 weeks. Forty patients accepted continuous 
      24-hour pH measurements after the fifth dose. The primary endpoint was ulcer 
      healing rate at week 4. RESULTS: The efficacy analyses were based on 235 
      patients. At week 4, 86.4%, 93.1%, 86.4%, and 89.8% patients treated with 5 mg 
      ilaprazole, 10 mg ilaprazole, 20 mg ilaprazole, and 20 mg omeprazole once daily, 
      respectively had ulcers healed (P=0.59). The majority of patients (>70%) became 
      asymptomatic after 4 weeks treatment. Both drugs with stipulated dosages 
      exhibited similar efficacy and safety profiles. Gastric acid suppression 
      increased with increasing dose of ilaprazole in pH study. CONCLUSIONS: Ilaprazole 
      is as tolerable, safe, and efficacious as omeprazole in the treatment of duodenal 
      ulcers, especially at a lower dose (10 mg/d ilaprazole vs. 20 mg/d omeprazole). 
      (ClinicalTrials.gov ID: NCT00953381).
FAU - Wang, Ling
AU  - Wang L
AD  - Department of Health Statistics, The Fourth Military Medical University, Xi'an, 
      Shaanxi, China.
FAU - Zhou, Liya
AU  - Zhou L
FAU - Lin, Sanren
AU  - Lin S
FAU - Hu, Haitang
AU  - Hu H
FAU - Xia, Jielai
AU  - Xia J
LA  - eng
SI  - ClinicalTrials.gov/NCT00953381
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Gastroenterol
JT  - Journal of clinical gastroenterology
JID - 7910017
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Benzimidazoles)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (Sulfoxides)
RN  - 776Q6XX45J (ilaprazole)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles
MH  - Adult
MH  - Anti-Ulcer Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Benzimidazoles/administration & dosage/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Duodenal Ulcer/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Omeprazole/administration & dosage/adverse effects/*therapeutic use
MH  - *Proton Pump Inhibitors/administration & dosage/adverse effects/*therapeutic use
MH  - Sulfoxides/administration & dosage/adverse effects/*therapeutic use
MH  - Treatment Outcome
EDAT- 2010/08/04 06:00
MHDA- 2011/07/14 06:00
CRDT- 2010/08/04 06:00
PHST- 2010/08/04 06:00 [entrez]
PHST- 2010/08/04 06:00 [pubmed]
PHST- 2011/07/14 06:00 [medline]
AID - 10.1097/MCG.0b013e3181e88515 [doi]
PST - ppublish
SO  - J Clin Gastroenterol. 2011 Apr;45(4):322-9. doi: 10.1097/MCG.0b013e3181e88515.